

# DIAGNOS

Interim Management Discussion & Analysis – Quarterly Highlights

Three-month and Nine-month Periods ended December 31, 2020

DIAGNOS Inc.

## Interim Management Discussion and Analysis – Quarterly Highlights

This Interim Management Discussion and Analysis – Quarterly Highlights (“MD&A”) of DIAGNOS Inc. and its subsidiaries (“DIAGNOS”, “the Corporation” or “we”), dated February 24, 2021 and approved by the board of directors on the same date, provides an update, as at December 31, 2020 and for the three-month period and the nine-month period ended December 31, 2020, to the last Corporation’s annual MD&A dated March 31, 2020. It should be read in conjunction with the December 31, 2020 interim condensed consolidated financial statements and accompanying notes. The currency used is the Canadian dollar, unless otherwise stated.

### **Description and Objective**

This MD&A is a narrative explanation, through the eyes of management, of the Corporation’s performance during the periods covered by the financial statements, and of the Corporation’s financial condition and future prospects. This MD&A complements and supplements the Corporation’s financial statements, but does not form part of the Corporation’s financial statements.

The objective of this MD&A is to improve the Corporation’s overall financial disclosures by providing a balanced discussion of the Corporation’s financial performance and financial condition.

### **Forward-looking statements**

This MD&A contains certain forward-looking statements with respect to the Corporation. By their nature, these forward-looking statements necessarily imply risks and uncertainties that could cause actual results to differ materially from those contemplated by these forward-looking statements. These risks and uncertainties include risks associated with the going concern assumption, market acceptance, competitive developments, the world economic situation and other factors. Except for ongoing obligations under securities laws to disclose all material information to investors, we disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

### **Non-GAAP financial measure**

This MD&A contains non-GAAP financial measures. A non-GAAP financial measure is a numerical measure of an issuer’s historical or future financial performance, financial position or cash flow that is not specified, defined or determined under the Corporation’s GAAP (as that term is defined in Regulation 52-107 respecting Acceptable Accounting Principles and Auditing Standards) and is not presented in the Corporation’s financial statements.

Working capital and cash liquidities are the only non-GAAP financial measures presented in this document. The working capital amount is obtained by subtracting accounts payable and accrued liabilities and other current liabilities from cash, non-restricted short-term investments, accounts receivable and other current assets. It is an indicator for assessing short-term solvency. Cash liquidities consist of cash and short-term investments.

## Going concern assumption


The Corporation's current level of revenue is not sufficient to cover its expenses and ongoing commitments. The Corporation's ability to generate positive cash flows from its operating activities is dependent on achieving and maintaining profitable operations. Since inception, the Corporation has been able to finance its activities and operate on a going concern basis through issuances of debt and equity instruments as well as benefiting from governmental assistance programs. Until it is able to generate cash flows from its operations to meet its operating and financial obligations, the Corporation intends to continue seeking additional financing through the issuance of debt and equity instruments. While the Corporation has been successful in securing financing in the past, there can be no assurance it will be able to continue doing so, that such sources of funding or initiatives will be available on terms acceptable to the Corporation. If the Corporation is unable to obtain sufficient additional funding, it may be unable to continue its operations, and amounts from the sale of assets might be less than the amounts reflected in the financial statements.

## Description of the Corporation and activities

DIAGNOS has built an Artificial Intelligence ("AI") platform called FLAIRE to provide assistance to general practitioners in interpreting medical imaging at the primary care facilities. The Corporation operates in Healthcare and offers image analysis services through Computer Assisted Retinal Analysis (CARA), a software tool, which assists health specialists in the detection of diabetic retinopathy. CARA is an in-house hosted web-based application that integrates fundus cameras with an image processing engine over a secure internet connection and has been developed by, and is proprietary to, DIAGNOS.

The common shares of DIAGNOS are currently listed on (i) the TSX Venture Exchange of the Toronto Stock Exchange under the symbol "ADK" and (ii) the OTCQB, under the symbol "DGNOF".

DIAGNOS group of entities is organized as follows:



## AI market in healthcare and trends

The AI market in healthcare has high growth opportunities due to rising needs of self-care monitoring in real-time. Globally, AI in healthcare market is driven by the ability to improve patient outcomes, increase in need for coordination between healthcare workforce & patients, rise in adoption of precision medicine, significant use of big data in the healthcare sector, and remarkable rise in venture capital investments. Key healthcare applications using AI at present include – Intelligent Diagnostics, Patient and Provider Data Management, Drug Discovery Process, and Medical Devices and Robotics. With its established CARA technology and worldwide presence, we believe DIAGNOS is well positioned to capture a sizeable portion of the AI market in healthcare.

Management also believes that, over the next several years, AI-based technologies will fundamentally transform the diagnostic imaging market where the focus would be towards meeting the rising demand for imaging examinations, prevent diagnostic errors, and enable sustained productivity increases rather than replacing the need for radiologists.

It is estimated that medical images account for 90% of the medical data which makes it the largest data source in healthcare industry. Nowadays, healthcare algorithms are created to get more accurate and quicker assessments. Presently, medical imaging is applied in many healthcare sectors such as tumour detection, tracking tumour development, blood flow visualization, medical interpretation and diabetic retinopathy detection.

## CARA

The Corporation has developed a proprietary set of algorithms and associated software platform to assist eye specialists in the detection of diabetic retinopathy. According to the Canadian Diabetes Association, diabetic retinopathy is the most common cause of blindness in people under age 65 and the most common cause of new blindness in North America. Also, according to the Canadian Diabetes Association, it is estimated that approximately 2 million individuals in Canada (i.e. almost all people with diagnosed diabetes) have some form of diabetic retinopathy. According to the World Health Organization, about 422 million people worldwide have diabetes, the majority living in low-and middle-income countries, and 1.6 million deaths are directly attributed to diabetes each year. Both the number of cases and the prevalence of diabetes have been steadily increasing over the past few decades.

Our application is named CARA, which stands for “Computer Assisted Retinal Analysis”. The Corporation’s management view is that this application will contribute to the increase in revenue streams based on the fact that automating the screening process for diabetic retinopathy will benefit the healthcare system.

The CARA suite of applications allows an eye care specialist to more clearly visualize both normal retinal landmarks (optic nerve, vascular system, macula, fovea), as well as pathological changes (exudates, haemorrhages, micro-aneurisms, neo-vascularisation).

Services rendered by the Corporation vary from image enhancement only, to turn-key solutions including deploying imaging equipment on a mobile basis using the Corporation’s staff.

The commercialization of CARA is done by our internal sales team and through our network of agents and resellers. Our solution CARA is currently being showcased at the CHUM, a major hospital in Montreal, Canada. Our focus is to (i) continue to build revenue and sales in emerging markets and (ii) substantially grow sales in Canada and in the USA, where we believe CARA offers a unique value proposition to payers and patients.

CARA can be deployed in many countries and has received certifications from regulatory bodies in Canada, the United States of America, the countries of the European Union, Mexico, the United Arab Emirates and Saudi Arabia.

## **Business model and main risks**

The Corporation's main line of business is the screening of diabetic patients for diabetic retinopathy.

Screening projects are classified into two categories; managed and standalone. Managed projects are those which require a full-time technician for each screening unit to manage the screening unit logistics, whereas standalone projects comprise one part-time technician and/or remote technical support to manage several screening units. In standalone projects, a camera is usually deployed at the screening site for the duration of the contract, after the part-time technician and/or remote technical support has trained site staff on how to acquire images.

Revenue arises from fees charged to analyse the retina of the eye image through the CARA web platform, usually on a per-transaction basis. The per-transaction fee varies based on the degree of deployment; managed or standalone. Revenue may also arise from fixed-amount subscription to the CARA platform. The Corporation also earns revenue from consulting services in the field of Artificial Intelligence.

The main risks related to its business model that the Corporation is exposed to include (i) concentration of customers since the Corporation's main source of revenue is derived from only one specific segment of healthcare, diabetic retinopathy, and (ii) product acceptance, since the CARA technology is (a) based on Artificial Intelligence, which is in development, and (b) not intended to make any diagnosis but rather to help the healthcare professionals in making diabetic retinopathy diagnosis assessments.

## **Significant event during the period**

### **Impact of the COVID-19 pandemic**

On March 11, 2020, the World Health Organization declared the recent outbreak of a novel and highly contagious form of coronavirus known as COVID-19 to be a pandemic. Since then, the Corporation's sales process has been somewhat impacted and screening activities have slowed down. It is currently impossible for the Corporation to clearly assess the full impact of this pandemic on the results for the current fiscal year, however, it should not significantly impact our ability to maintain our operations. The Corporation was able to retain all of its key employees and to qualify for various federal financial relief programs. The Corporation is monitoring the situation closely and may take additional measures to reduce its costs and preserve its liquidities.

### **Financing activities**

During the quarter ended December 31, 2020, the Corporation received an aggregate amount of \$687,740 resulting from the exercises of 4,114,921 stock warrants and 145,000 stock options.

### **Leases**

During the quarter ended September 30, 2020, the Corporation signed a new lease for its head office. The minimum monthly payment amounts to \$6,135 for a term of 60 months ending August 31, 2025. The signing of a new lease resulted in an increase in right-of-use assets of \$301,512.

## Quarterly Highlights

This section provides a short discussion of all material information about the Corporation's operations, liquidity and capital resources.

### Financial condition

The comparative financial information contained in this section is derived from the Corporation's interim condensed consolidated financial statements.

	As at	
	December 31, 2020	March 31, 2020
	\$	
Cash and short-term investments	1,460,094	1,872,107
Accounts receivable	155,697	343,682
Other current assets	28,617	122,285
Non-current assets	384,075	95,873
<b>Total assets</b>	<b>2,028,483</b>	<b>2,433,947</b>
Accounts payable and accrued liabilities	358,476	273,057
Other current liabilities	225,004	307,977
Non-current liabilities	277,864	33,742
Shareholders' equity	1,167,139	1,819,171
<b>Total liabilities and shareholders' equity</b>	<b>2,028,483</b>	<b>2,433,947</b>
<b>Working capital</b>	<b>1,060,928</b>	<b>1,757,040</b>
<b>Decrease in working capital</b>	<b>(696,112)</b>	

### *Analysis of the variation in working capital*

The decrease in working capital of \$696,112 for the nine-month period ended December 31, 2020 is mainly attributable to:

	\$
Net loss	(1,421,279)
Issuance of common shares	687,740
Others	37,427
	<u>(696,112)</u>

To improve its working capital in the near term, the intentions of the Corporation are discussed in the below section "Cash flows".

## Financial performance

The following comparative financial information for the comparative three-month and nine-month periods ended December 31, 2020 is derived from the Corporation's interim condensed consolidated financial statements.

### Comparative results

	Three-month period ended		Nine-month period ended	
	December 31,		December 31,	
	2020	2019	2020	2019
	\$		\$	
Revenue	77,877	90,351	205,354	253,842
Operating expenses	(646,631)	(614,312)	(1,847,633)	(1,964,708)
Other income	12,149	-	259,179	17,056
Interest expense	(16,174)	(43,528)	(38,179)	(252,518)
Gain on disposal of capital assets	-	-	-	2,833
Loss on settlement of debt	-	-	-	(175,722)
	(650,656)	(657,840)	(1,626,633)	(2,373,059)
<b>Net loss</b>	<b>(572,779)</b>	<b>(567,489)</b>	<b>(1,421,279)</b>	<b>(2,119,217)</b>
(Increase) decrease in net loss	(5,290)		697,938	

The variations in net loss are attributable to:

	Three-month period ended	Nine-month period ended
	December 31, 2020	
	\$	
Decrease in revenue	(12,474)	(48,488)
Decrease in costs of services and research and development	14,244	175,197
Increase in selling and administrative expenses	(46,563)	(58,122)
Increase in other income	12,149	242,123
Decrease in interest expense	27,354	214,339
Decrease in gain (loss) on disposal of capital assets	-	(2,833)
Decrease in loss on settlement of debt	-	175,722
	(5,290)	697,938

*Detailed analysis of the variations in net loss*

Revenue

The following table presents the comparative revenues by country. It is followed by an analysis of the main variations.

	Three-month period ended December			Nine-month period ended December		
	31,			31,		
	2020	2019	Variance	2020	2019	Variance
	\$			\$		
Canada	71,116	59,313	11,803	168,578	139,365	29,213
United States of America	5,831	15,778	(9,947)	33,969	59,525	(25,556)
Colombia	930	-	930	2,807	-	2,807
Bangladesh	-	18	(18)	-	13,126	(13,126)
United Arab Emirates	-	11,860	(11,860)	-	35,760	(35,760)
Costa Rica	-	2,647	(2,647)	-	2,647	(2,647)
Saudi Arabia	-	735	(735)	-	3,419	(3,419)
	<u>77,877</u>	<u>90,351</u>	<u>(12,474)</u>	<u>205,354</u>	<u>253,842</u>	<u>(48,488)</u>

Canada

80% of revenues from Canada, for the nine-month period ended December 31, 2020, were attributable to data interpretation consulting services rendered to one company active in the mining sector (nine-month period ended December 31, 2019 - 67%). The increase of \$29,213, for the nine-month period ended December 31, 2020, is mainly due to the increase in the level of data interpretation consulting services rendered to the client active in the mining sector.

United States of America

Revenues are derived from the healthcare sector (CARA). The decrease of \$25,556 for the nine-month period ended December 31, 2020 is attributable to the decrease in the volume of screenings mainly due to the impact of the Covid-19 pandemic.

Bangladesh

Revenues are derived from the healthcare sector (CARA). The decrease of \$13,126 for the nine-month period ended December 31, 2020 is attributable to the non-renewal of sales agreements.

United Arab Emirates

Revenues are derived from the healthcare sector (CARA). The decrease of \$35,760 for the nine-month period ended December 31, 2020 is attributable to the non-renewal of sales agreements.

Saudi Arabia

Revenues are derived from the healthcare sector (CARA). The decrease of \$3,419 for the nine-month period ended December 31, 2020 is attributable to the absence of screenings.



#### Cost of services and research and development (R&D)

The decreases of \$14,244 for the three-month period ended December 31, 2020 and of \$175,197 for the nine-month period ended December 31, 2020 are mainly due to the decrease in headcount and the decrease in consulting expenses.

#### Selling and administrative expenses

The increase of \$58,122, for the nine-month period ended December 31, 2020, is attributable to:

	<u>\$</u>
Consulting	181,538
Payroll	(43,552)
Travel and living	(41,692)
Rent	(33,345)
Others	(4,827)
	<u>58,122</u>

#### Other income

The increases of \$12,149 for the three-month period ended December 31, 2020 and of \$242,123 for the nine-month period ended December 31, 2020 are mainly attributable to money received under the Canada Emergency Wage Subsidy program.

#### Interest expense

The decrease of \$214,339, for the nine-month period ended December 31, 2020, is mainly attributable to the May 15, 2019 redemption of the convertible debt.

#### Loss on settlement of debt

The amount of \$175,722, for the nine-month period ended December 31, 2020, arose from the redemption, on May 15, 2019, of the outstanding convertible debentures and 85% of the outstanding notes. It is comprised of an amount of \$120,130, representing the difference between the fair value of the shares issued and the amortized cost of the debt and interest amounts, as well as an amount of \$55,592 representing the fees paid in connection with the redemption.

## Cash flows

For the comparative nine-month period ended December 31, 2020, cash liquidities varied as follows:

	Nine-month period ended December 31,		
	2020	2019	Variance
	\$		
Cash liquidities <sup>1</sup> at beginning of period	<b>1,872,107</b>	<b>693,954</b>	
Receipts from:			
Clients	244,528	233,563	10,965
Grants	273,979	63,719	210,260
Equity financings	687,500	532,166	155,334
Loans	40,000	647,800	(607,800)
	<b>1,246,007</b>	<b>1,477,248</b>	<b>(231,241)</b>
Disbursements:			
Payroll, suppliers and others	(1,474,024)	(1,811,096)	337,072
Loans	(150,000)	-	(150,000)
Interests	(33,996)	(22,500)	(11,496)
	<b>(1,658,020)</b>	<b>(1,833,596)</b>	<b>175,576</b>
Net change in liquidities	<b>(412,013)</b>	<b>(356,348)</b>	<b>(55,665)</b>
Cash liquidities <sup>1</sup> at period end	<b>1,460,094</b>	<b>337,606</b>	

*Note 1: Cash liquidities consist of cash and short-term investments*

Until it is able to generate a level of sales sufficient to finance its operations and financial obligations, the Corporation will need to rely on further financing. Since inception, the Corporation has been able to finance its activities and operations through issuances of debt and equity instruments as well as from governmental assistance programs.

## Capital structure

	As at		
	December 31, 2020	March 31, 2020	Variance
	Number		
Common shares	65,625,925	61,366,004	4,259,921
Stock warrants	4,170,169	10,200,090	(6,029,921)
Conversion options into common shares	-	937,500	(937,500)
Stock options	6,177,000	4,396,000	1,781,000
	<u>75,973,094</u>	<u>76,899,594</u>	<u>(926,500)</u>

The increase of 4,259,921 in the number of common shares is attributable to exercises of stock warrants and stock options.

The decrease of 6,029,921 in the number of stock warrants is attributable to:

	Number
Exercises	4,114,921
Expiries	1,915,000
	<u>6,029,921</u>

The decrease of 937,500 in the number of conversion options into common shares is attributable to expiries.

The increase of 1,781,000 in the number of stock options is attributable to:

	Number
Grants	1,950,000
Exercises	(145,000)
Cancellation	(24,000)
	<u>1,781,000</u>

**Head Office**

DIAGNOS Inc.  
7005 Taschereau Blvd.  
Suite 265  
Brossard, Quebec J4Z 1A7  
450 678-8882 or 877 678-8882

**Stock Exchange Listing**

DIAGNOS Inc. shares are listed on the TSX Venture Exchange under the symbol ADK and on the OTCQB under the symbol DGNOF.

**Transfer Agents and Registrar**

Computershare Trust Company of Canada

**Auditor**

Raymond Chabot Grant Thornton LLP